Gaslightwala Abizer
Gaslightwala Abizer, CEO, reported a transaction classified as exercise at Akari Therapeutics Plc involving 7733.000000 shares for an estimated $3.09. Reported holdings after the transaction were 41173.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 14, 2026
- Filing date
- Oct 16, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
AKTX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001493152-26-047454 American Depositary Shares representing Ordinary Shares
- Transaction date
- Oct 14, 2026 Filed Oct 16, 2026, 09:20 PM · 2d delay
- Shares
- 7,733 sh $0.00 per share
- Estimated value
- $3 Computed from shares × price
- Holdings after
- 41,173 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
+10 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CEO
- F1
On August 18, 2026, the Reporting Person was granted an option to purchase 174,000 American Depository Shares ("ADSs"). This option grant is subject to forfeiture if shareholder approval of a proposed…
- F2
The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
- F3
The pre-funded warrants remain exercisable until fully exercised.
- F4
On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all ac…
- F5
On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Privat…
- F6
The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.
0 other transactions
0 recent txs